Feasibility Study for Identifying Anti Capsular Antibody Protection Against Invasive Group B Streptococcus (GBS) Disease in Newborns of 0-6 Days Age (Early Onset Disease [EOD]) as Well as Among Infants of 7-90 Days Age (Late Onset Disease [LOD])

Streptococcus Agalactiae Clinical Trial

Official title:
Feasibility Study for Identifying a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged Less ≤90 Days

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate antibody levels against Group B streptococcus in mothers and the risk of developing invasive Group B streptococcus disease in newborns of less than 6 days age as well as infants of age less than 90 days age.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Streptococcus Agalactiae

Clinical Trial Details

NCT number	NCT01888471
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	N/A
Start date	December 11, 2013
Completion date	July 14, 2014

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04165551` - Evaluation of the Consumption of a Probiotic on the Load of S. Agalactiae.	Phase 1
Completed	`NCT00920530` - Real-Time PCR for the Detection of Vaginal Group B Streptococcus Carriage: a Medico-Economic Study	N/A
Completed	`NCT05005169` - CCA of SGB PCR Versus SGB Culture at 35-38 SA in the Optimization of Intrapartum Antibiotic Prophylaxis	N/A
Completed	`NCT02690181` - Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.	Phase 2
Completed	`NCT02046148` - Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women	Phase 2